All Oncology News

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that hematologist and medical oncologist Andrea Katz, MD has joined the statewide practice.

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer.

Regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality. However, the chances of being diagnosed with advanced breast cancer are higher among women who are Black or Hispanic/Latinx, overweight, or obese.

Findings from the EV-302 trial presented at the 2023 ESMO Congress revealed that the combination of enfortumab vedotin and pembrolizumab may become the preferred frontline standard of care for patients with locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility.

Researchers at Dana-Farber Cancer Institute have found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.

Researchers at University of Utah Health have designed new digital tools that use relevant information from patient health records to prompt doctors to consider lung cancer screening for high-risk patients and provide personalized guidance on screening.

It is never too early to think about interviewing for your next opportunity. Even if you have already committed to your next career move, learning how to interview will serve you well as you may be considered for different positions within the organization.

Michael P. Stany, MD, discusses the optimization of PARP inhibitors in the upfront maintenance setting of ovarian cancer, the benefit of novel targets and immunotherapy combinations, and the role of immunotherapy in the treatment of advanced endometrial cancer.

Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.

Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.

The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

WebMD awarded Huntsman Cancer Institute at the University of Utah its highest honor, the 2023 WebMD Elite Choice Award.

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines for Non–Small Cell Lung Cancer for 2024 to include 2 new category 1 recommendations for amivantamab alongside chemotherapy in patients with treatment-naive, EGFR-mutated advanced NSCLC.

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

The Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.